Table 3

Multivariate overall survival analysis on subgroup patients with ipilimumab week 12

	HR	Lower 95% CI	Upper 95% CI	P value
(A) Ipilimumab levels as a continuous variable
Multivariable analysis 1 (n=31, events=25)
Log_10 CXCL11 pretreatment	7.38	1.76	30.9	0.006
Sex
Female	Reference
Male	1.37	0.55	3.42	0.495
Age	0.98	0.94	1.02	0.271
ECOG
0	Reference
1–2	0.94	0.32	2.74	0.908
Prior immunotherapy
No	Reference
Yes	0.53	0.21	1.35	0.186
Log_10 ipi week 12	0.78	0.21	2.8	0.697
(B) Ipilimumab levels as a categorical variable
Multivariable analysis 2 (n=36, events=30)
Log_10 CXCL11 pre-treatment	5.6	1.3	24.02	0.02
Sex
Female	Reference
Male	1.49	0.6	3.69	0.394
Age	0.98	0.94	1.02	0.283
ECOG
0	Reference
1–2	0.98	0.33	2.85	0.964
Prior immunotherapy
No	Reference
Yes	0.43	0.16	1.16	0.097
ipi week 12 (median cut-off)
≤24.17 (mg/mL)	Reference
>24.17	0.48	0.18	1.29	0.145